Commission continues decision on HHS monkeypox provider agreement after questions on scope and oversight

The Utah County Commission on Sept. 14 deferred action on a federal provider agreement that would allow the county to receive monkeypox vaccine doses from the national strategic stockpile, voting to continue the item for two weeks so staff could supply additional information about vaccine formulation, reporting obligations and potential future changes to the provider terms.

Health department staff explained that the agreement requires cold‑chain storage, entry into electronic medical records, reporting adverse events to VAERS, and that the vaccine doses would be supplied free from the federal government and distributed through the state. County epidemiology told commissioners the county had 13 confirmed monkeypox cases; staff said two deaths nationally were under investigation.

Public commenters urged caution. One speaker said the agreement mentioned ACAM2000, which he described as not FDA approved; county epidemiology and the immunization director clarified the county is offering Jynneos and said Jynneos received FDA approval in 2019. Nancy Flake, director of the county immunization department, told the commission, "We're giving the Jynneos, which is ... FDA approved in 02/2019." Curtis Jones, epidemiology, summarized eligibility criteria the county would use (close contacts and people at elevated risk, including certain men who have sex with men) and said administration is voluntary.

Commissioners and county counsel discussed a clause that incorporates web links and allows HHS to post future changes to the provider agreement. Counsel advised that the agreement functions as an acknowledgement for access to doses and that the county could stop administering doses and return them if it disagreed with later changes; commissioners asked staff to monitor the HHS webpage and to bring substantial changes back to the legislative body for review. The commission voted 3–0 to continue the item to the Sept. 28 meeting.

The continuation gives staff time to assemble adverse‑event data and confirm vendor and formulation details and to propose an internal monitoring process for web‑posted changes.